<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimicrobial treatment of intravascular catheter-related bloodstream infection (CRBSI) according to the pathogen isolated (with antibiotic susceptibilities reported)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimicrobial treatment of intravascular catheter-related bloodstream infection (CRBSI) according to the pathogen isolated (with antibiotic susceptibilities reported)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antimicrobial treatment of intravascular catheter-related bloodstream infection (CRBSI) according to the pathogen isolated (with antibiotic susceptibilities reported)</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Pathogen</td> <td class="subtitle1">Preferred<br/> antimicrobial agents and dosing (adult)</td> <td class="subtitle1">Alternative<br/> antimicrobial agents and dosing (adult)</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Staphylococci</td> </tr> <tr> <td class="indent1">Methicillin susceptible</td> <td> <p>Nafcillin 2 g IV every 4 hours</p> <p>Oxacillin 2 g IV every 4 hours</p> <p>Cefazolin 2 g IV every 8 hours</p> Flucloxacillin* 2 g IV every 6 hours</td> <td>Vancomycin (dosing as summarized below)</td> </tr> <tr> <td class="indent1">Methicillin resistant</td> <td>Vancomycin:<sup>¶</sup> <ul class="decimal_heading"> <li>Loading dose: 20 to 35 mg/kg IV once</li> <li>Initial maintenance dose and interval: determined by nomogram; typically 15 to 20 mg/kg IV every 8 to 12 hours for most patients with normal kidney function</li> <li>Subsequent dose and interval adjustments based on AUC-guided (preferred) or trough-guided serum concentration monitoring</li> </ul> </td> <td>Daptomycin<sup>Δ</sup> 6 to 10 mg/kg IV every 24 hours</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Enterococci<sup>◊</sup></td> </tr> <tr> <td class="indent1">Ampicillin susceptible</td> <td>Ampicillin 2 g IV every 4 hours</td> <td>Vancomycin (dosing as summarized above)</td> </tr> <tr> <td class="indent1">Ampicillin resistant, vancomycin susceptible</td> <td>Vancomycin (dosing as summarized above)</td> <td> <p>Daptomycin<sup>Δ</sup> 6 to 10 mg/kg IV every 24 hours</p> Linezolid 600 mg IV (or orally) every 12 hours</td> </tr> <tr> <td class="indent1">Ampicillin resistant, vancomycin resistant</td> <td>Daptomycin<sup>Δ</sup> 6 to 10 mg/kg IV every 24 hours</td> <td>Linezolid 600 mg IV (or orally) every 12 hours</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Enterobacteriaceae (examples include <em>E. coli</em>, <em>Klebsiella</em> spp, <em>Enterobacter</em> spp)</td> </tr> <tr> <td class="indent1">ESBL negative</td> <td>Ceftriaxone 2 g IV every 24 hours</td> <td>Ciprofloxacin 400 mg IV every 12 hours</td> </tr> <tr> <td class="indent1">ESBL positive</td> <td> <p>Imipenem 500 mg IV every 6 hours</p> <p>Meropenem 1 g IV every 8 hours</p> Ertapenem 1 g IV every 24 hours</td> <td>Ciprofloxacin 400 mg IV every 12 hours</td> </tr> <tr> <td class="subtitle2_left" colspan="3"><em>Pseudomonas</em> spp<sup>§</sup></td> </tr> <tr> <td class="indent1"> </td> <td> <p>Ceftazidime 2 g IV every 8 hours</p> <p>Cefepime 2 g IV every 8 hours</p> Piperacillin-tazobactam 4.5 g IV every 6 hours<sup>¥</sup></td> <td> <p>Imipenem 500 mg IV every 6 hours</p> <p>Meropenem 1 g IV every 8 hours</p> Ciprofloxacin 400 mg IV every 8 hours</td> </tr> </tbody></table></div><div class="graphic_lgnd">Dosing recommendations are for adult patients with normal organ function. For more detail, including duration of treatment and dosage adjustments (eg, for organ impairment), refer to the clinical topic review of intravascular non-hemodialysis CRBSI and individual drug information monographs included within UpToDate.</div><div class="graphic_footnotes">ESBL: extended-spectrum beta-lactamase.<br/>* Flucloxacillin is not available in the United States and Canada.<br/>¶ Refer to UpToDate topic on vancomycin dosing for further discussion.<br/>Δ Standard daptomycin dosing (as approved by the US Food and Drug Administration) for bloodstream infection is 6 mg/kg IV every 24 hours. Because daptomycin exhibits concentration-dependent killing, some experts recommend doses of up to 8 to 10 mg/kg IV once daily, which appear safe; further study is needed.<br/><span class="lozenge">◊</span> Refer to the UpToDate topic on treatment of catheter infections for further discussion of issues related to treatment of infection due to Enterococcus spp.<br/>§ Combination therapy for empiric treatment of CRBSI due to Pseudomonas spp is warranted for patients with sepsis, neutropenia, or severe burns. In such cases, an aminoglycoside (such as gentamicin or tobramycin) may be administered in combination with one the agents listed above. In the setting of renal insufficiency or in institutions with high frequency of aminoglycoside resistance, a fluoroquinolone may be used as a second agent. Once susceptibility data are available, directed therapy with a single active agent is appropriate.<br/>¥ Dosing is expressed as the combined amount of piperacillin and tazobactam and is intended for administration by the traditional infusion method over 30 minutes. Extended infusion administration may be considered; refer to the UpToDate clinical topic review of prolonged infusions of beta-lactam antibiotics.</div><div class="graphic_reference">Reference:

<ol>
<li>Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519.</li>
</ol></div><div id="graphicVersion">Graphic 79387 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
